Features
A Novel Filtration Technique to Treat Open-angle Glaucoma
Minimally invasive microsclerostomy (MIMS) is a bleb-forming MIGS procedure that is short, simple, and stentless.
By Lilit Voskanyan, MD, PhD
Practical Tips for Using iStent Infinite
The new design of this MIGS device makes it easier to achieve good results if you follow these strategies for proper stent placement.
By Sahar Bedrood, MD, PhD
Premium IOLs for POAG Patients
Expand the Toolbox with Multifocal and EDOF Lenses.
By Zarmeena Vendal, MD
Optimizing Drop Size in Ophthalmic Applications
A review of literature on the benefits of smaller drop sizes and tips for using the Nanodropper to dispense medication.
By Constance O. Okeke, MD, MSCE
Web Exclusives
Protecting the Ocular Surface
A comprehensive overview of treating DED in patients with glaucoma.
By Courtney Bovee, MD
Departments
From the Editor: Balancing Quality of Life and Glaucoma
By Nathan M. Radcliffe, MD
Bio-scaffolded Cyclodialysis Shows Promising Results
Two physicians discuss the procedure, which uses allograft tissue to open a drainage cleft into the suprachoroidal space.
By Jim Gallagher, senior managing editor
Medicare’s MIGS LCD Finalized
A highly anticipated Medicare coverage policy for microinvasive glaucoma surgery establishes restrictions on coverage.
By Kevin J. Corcoran, COE, FNAO
News
Regeneron Leaders Recognized for Innovation at Eyecelerator 2024
Drs. Schleifer and Yancopoulos received the Eyecelerator Innovation Award and discussed the long and winding road to success.
By Jim Gallagher, senior managing editor
An Update on SLT Clinical Trials
The ongoing COAST trial hopes to answer the question of which selective laser trabeculoplasty treatment approach is most effective.
By Jim Gallagher, senior managing editor
Supported Content
Leading With the Procedure
How (and why) to put interventional glaucoma into practice
By Brian M. Shafer, MD, Mark J. Gallardo, MD
Considering the Time and Money Involved in Prior Authorizations
Getting patients off medications with MIGS procedures, SLT, or procedural pharmaceuticals can ultimately benefit both them and the practice
By Inder Paul Singh, MD
Early iStent infinite Feedback
IOP control in cataract or standalone procedures
By Christy Benson, MD